Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
homoharringtonine + cytarabine + daunorubicin
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The HAD regimen is a combination chemotherapy protocol consisting of homoharringtonine (HHT), cytarabine (Ara-C), and daunorubicin (DNR). It is primarily being investigated by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, for the treatment of acute myeloid leukemia (AML), with a specific focus on patients harboring CEBPA double mutations (CEBPAdm). Homoharringtonine is a plant alkaloid that inhibits protein synthesis by binding to the ribosome; cytarabine is a nucleoside analog that interferes with DNA synthesis by inhibiting DNA polymerase; and daunorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. This combination therapy targets rapidly dividing leukemic cells through multiple synergistic mechanisms and is being compared against the standard 3+7 induction regimen in clinical trials.
- Other names
- Intermediate-dose HAD regimen
02
Targets
DNADNA polymerase familyRibosomeTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on homoharringtonine + cytarabine + daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on homoharringtonine + cytarabine + daunorubicin.